BOULDER, CO, November 12, 2017 – AmideBio LLC, a privately-held biopharmaceutical company, announced today that Dr. David L. Snitman has joined its business advisory board. Dr. Snitman has extensive experience with company financing as well as building strategic alliances with the pharmaceutical industry. He will be a huge asset to the company as it develops its pipeline of novel drugs targeting diabetes and other metabolic diseases.
“We are delighted to have Dr. Snitman join the AmideBio Advisory Board as we develop our pipline of drug candidates targeting serious unmet medical needs,” said Dr. Misha Plam, President and CEO of Amide Bio. “Dr. Snitman’s knowledge of pharmaceutical drug development and financing, combined with his extensive experience in negotiating and managing strategic partnerships across the pharmaceutical industry will be immensely valuable to us.“
“I am excited to be joining AmideBio’s advisory board. The Company has an impessive pipeline of drug candidates that could significantly impact the way diabetes and congenital hyperinsulinism are treated,” said Dr. David L. Snitman. “I am impressed by the quality and novelty of research at AmideBio as well as the team driving to help patients afflicted with these treatment-challenged diseases.”
Dr. Snitman is currently a principal at DL SNITMAN LLC, a consulting firm providing business development services to the biotechnology industry. Dr. Snitman is a co-founder of Array BioPharma and served as Chief Operating Officer & Vice President, Business Development from 1998 to 2015. He was a member of Array’s Board of Directors from May 1998 to October 2012. Prior to forming Array, Dr. Snitman held senior positions with Amgen Inc. including Associate Director, New Products and Technology, and Manager of Amgen’s Boulder research facility. Dr. Snitman received a B.S. in chemistry from Northeastern University and obtained a Ph.D. in the synthesis of natural products from the University of Colorado. He was an NIH Postdoctoral Fellow at the Massachusetts Institute of Technology.
AmideBio is a biotechnology company leveraging its proprietary BioPure platform technology to deliver difficult-to-manufacture peptides cost effectively to the pharmaceutical and biotech industry, while also building a pipeline of novel biotherapeutics. AmideBio’s proprietary technology enables the rapid and economical manufacture of peptides of any length with unprecedented purity. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing, and internal research and development of novel biotherapeutics aimed at metabolic, inflammatory and neurodegenerative diseases.